Jean-Christophe Tellier, UCB CEO (Jasper Jacobs/Belga/Sipa USA/Sipa via AP Images)

UCB en­ters gene ther­a­py space, ink­ing li­cense agree­ment for epilep­sy and neu­rode­gen­er­a­tion re­search

UCB may not have any gene ther­a­py can­di­dates on the mar­ket or pub­licly in its pipeline, but that hasn’t stopped the phar­ma from ink­ing a mul­ti-year li­cense agree­ment with Clear­Point Neu­ro to work on drug de­liv­ery plat­forms for UCB’s gene ther­a­py port­fo­lio, ac­cord­ing to the com­pa­nies.

As part of the agree­ment, UCB will use Clear­Point Neu­ro’s tech and ser­vices to de­vel­op and com­mer­cial­ize UCB’s gene ther­a­py prod­ucts and Clear­Point will re­ceive suc­cess-based mile­stone pay­ments. More fi­nan­cial de­tails of the agree­ment weren’t de­scribed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.